Crinetics Pharmaceuticals Total Assets Growth & History (CRNX)
Crinetics Pharmaceuticals's total assets was $1.13B for fiscal 2025.
View full Crinetics Pharmaceuticals company overviewCrinetics Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.13B | −$308.3M | −21.49% |
| 2024 | 2024-12-31 | $1.43B | $799.2M | +125.79% |
| 2023 | 2023-12-31 | $635.4M | $283.2M | +80.41% |
| 2022 | 2022-12-31 | $352.2M | $1.2M | +0.33% |
| 2021 | 2021-12-31 | $351.0M | $167.6M | +91.35% |
| 2020 | 2020-12-31 | $183.4M | $53.1M | +40.70% |
| 2019 | 2019-12-31 | $130.4M | −$41.0M | −23.94% |
| 2018 | 2018-12-31 | $171.4M | $155.8M | +998.95% |
| 2017 | 2017-12-31 | $15.6M | — | — |
Crinetics Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.32B | $32.3M | +2.51% |
| Q1 2026 | 2026-03-31 | $1.40B | $40.0M | +2.94% |
| Q4 2025 | 2025-12-31 | $1.13B | −$308.3M | −21.49% |
| Q3 2025 | 2025-09-30 | $1.20B | $258.7M | +27.59% |
| Q2 2025 | 2025-06-30 | $1.29B | $354.0M | +37.84% |
| Q1 2025 | 2025-03-31 | $1.36B | $383.2M | +39.17% |
| Q4 2024 | 2024-12-31 | $1.43B | $799.2M | +125.79% |
| Q3 2024 | 2024-09-30 | $937.4M | $295.8M | +46.11% |
| Q2 2024 | 2024-06-30 | $935.5M | $642.3M | +219.02% |
| Q1 2024 | 2024-03-31 | $978.2M | $664.1M | +211.50% |
| Q4 2023 | 2023-12-31 | $635.4M | $283.2M | +80.41% |
| Q3 2023 | 2023-09-30 | $641.5M | $256.7M | +66.68% |
| Q2 2023 | 2023-06-30 | $293.3M | −$128.5M | −30.46% |
| Q1 2023 | 2023-03-31 | $314.0M | −$19.3M | −5.78% |
| Q4 2022 | 2022-12-31 | $352.2M | $1.2M | +0.33% |
| Q3 2022 | 2022-09-30 | $384.9M | $175.5M | +83.84% |
| Q2 2022 | 2022-06-30 | $421.7M | $204.8M | +94.41% |
| Q1 2022 | 2022-03-31 | $333.3M | $169.7M | +103.78% |
| Q4 2021 | 2021-12-31 | $351.0M | $167.6M | +91.35% |
| Q3 2021 | 2021-09-30 | $209.4M | $9.0M | +4.51% |
| Q2 2021 | 2021-06-30 | $216.9M | −$193,000 | −0.09% |
| Q1 2021 | 2021-03-31 | $163.6M | $39.7M | +32.02% |
| Q4 2020 | 2020-12-31 | $183.4M | $53.1M | +40.70% |
| Q3 2020 | 2020-09-30 | $200.3M | $57.8M | +40.56% |
| Q2 2020 | 2020-06-30 | $217.1M | $62.0M | +39.94% |
| Q1 2020 | 2020-03-31 | $123.9M | −$42.9M | −25.71% |
| Q4 2019 | 2019-12-31 | $130.4M | −$41.0M | −23.94% |
| Q3 2019 | 2019-09-30 | $142.5M | −$34.2M | −19.34% |
| Q2 2019 | 2019-06-30 | $155.1M | $80.4M | +107.69% |
| Q1 2019 | 2019-03-31 | $166.8M | — | — |
| Q4 2018 | 2018-12-31 | $171.4M | $155.8M | +998.95% |
| Q3 2018 | 2018-09-30 | $176.7M | — | — |
| Q2 2018 | 2018-06-30 | $74.7M | — | — |
| Q4 2017 | 2017-12-31 | $15.6M | — | — |
Crinetics Pharmaceuticals total assets trends
Over the last five fiscal years, Crinetics Pharmaceuticals's total assets increased from $183.4M to $1.13B, a change of $942.8M. The latest reported quarter, Q2 2026, shows $1.32B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Crinetics Pharmaceuticals source filings ↗